By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Great Emphasis is Put on Research.

EUR 700 Million for Vienna

ground-breaking ceremony at Boehringer © Boehringer Ingelheim

The expansion drive represents the largest single investment in the history of the company, and the largest corporate investment in Vienna since the construction of the General Motors factory in Aspern in 1979. The new facility, which will be put into operation in 2021, will produce biopharmaceuticals in the future with the help of cell cultures.

“This investment comprises a sustainable commitment of the management which secures the Vienna site for decades”, says Philipp von Lattorff, Managing Director of Boehringer Ingelheim Regional Center Vienna. Up until now, Boehringer Ingelheim has produced drugs in the Austrian capital with the help of yeasts and bacteria. The new cell culture facility is a response on the part of the company to fast growing demand for biopharmaceutical drugs. As one of the world’s leading contract manufacturers in this sector, the project will help us further strengthen our market position”, explains Wolfgang Baiker, Global Head of Biopharmaceuticals and Production at Boehringer Ingelheim.

About the Boehringer Ingelheim Regional Center Vienna

The Boehringer Ingelheim Regional Center Vienna is responsible for the Boehringer Ingelheim business with prescription medications and veterinary medicines in Austria as well as in more than 30 countries in Central and Eastern Europe, Central Asia, Switzerland and Israel. In addition, all of the clinical research in the region is managed from Vienna. Vienna is the center of cancer research as well as where the Group’s biopharmaceutical research, development and production takes place. Boehringer Ingelheim is also involved in basic research at the Research Institute of Molecular Pathology (IMP) in Vienna. Boehringer Ingelheim thus ranks among the most research-intensive pharmaceutical companies in Austria. In fiscal year 2016, the Regional Center Vienna achieved total sales of EUR 821.5 million and employed 3,470 people in Central and Eastern Europe, including 1,629 in Austria. Thanks to the new production facility, the number of employees will increase to about 2,100 in the coming years.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • ABA's Virtual Open Day Reloaded

    01.10.2020/ 14pm - 15pm (CET), Virtual Event

  • Austria - Oportunități pentru companii românești

    05.10.2020/ | 16:30 - 18:30, București, Romania

Austria Map

Find the perfect location for your company

Storage and distribution for Eastern Europe is more economical from Vienna than from Prague or Budapest. Because shipping business between the individual reform nations is barely developed, whereas neary every Eastern destination is serviced from Vienna several times a week.

Hewlett Packard Austria

Logo
More testimonials

news from the business location Austria

Investment for augmented reality startup Amlogy

Augmented reality (AR) has always been a passion for Arkadi Jeghiazaryan.

Innovations from Vienna are a Growth Driver

Multinational companies invest € 2 billion in research in Austria every year. Many of the subsidiaries based in Austria carry out research and development activities in the Alpine Republic. Our company also does so. Ottobock has been operating in Austria for more than 50 years.

More news All blog posts